세계의 인간 광견병 백신 시장 : 부문별 예측(2025-2030년)

The Human Rabies Vaccines Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.05 billion in 2024, and is projected to grow at a CAGR of 4.51%, to USD 1.37 billion by 2030.

Human rabies vaccines are critical in preventing the fatal viral disease of rabies, transmitted through bites or scratches by infected animals. The scope of rabies vaccines encompasses both pre-exposure prophylaxis, especially for high-risk individuals such as veterinarians or travelers to endemic regions, and post-exposure prophylaxis for bite victims. The necessity of these vaccines stems from the near 100% mortality rate once symptoms appear, highlighting the essential role they play in global public health. The primary end-users are healthcare facilities, veterinary clinics, and travel clinics, with substantial applications in scenarios necessitating emergency or preventive interventions.

The market for human rabies vaccines is influenced by several factors, including rising awareness about the disease and increasing government initiatives for immunization programs. Furthermore, the expansion of healthcare infrastructure in developing regions presents significant growth opportunities. Notably, the growing emphasis on preventive healthcare and advances in biotechnology provide a fertile ground for innovation. Opportunities also lie in developing vaccines that require fewer doses or are needle-free, thus improving accessibility and adherence.

However, the market faces limitations, including high costs of vaccine production, logistical challenges in distribution, especially in rural areas, and competition from alternative prophylactics and treatments. Challenges also include potential adverse reactions and misinformation leading to vaccine hesitancy, which can hinder market penetration.

Innovation can thrive by focusing on the development of more effective, easily administrable vaccines and improved storage solutions to enhance supply chain efficiency. Also, research into creating single-shot vaccines or those with extended immunity duration could revolutionize the field. This market is characterized by its highly regulated nature, with an emphasis on safety and efficacy, which can both motivate and restrict operational flexibility for companies. Ultimately, businesses that leverage partnerships with governments and NGOs, invest in education campaigns, and drive technological advancements will likely capitalize on the evolving landscape of the human rabies vaccine market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Rabies Vaccines Market

The Human Rabies Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of mortality due to rabies
  • Increasing number of pets and stray dogs
  • Lower rate of immunization in pets and lack of pet management services
• Market Restraints
  • Dearth of vaccine supply in remote areas
• Market Opportunities
  • Proliferation in research and development activities to introduce effective vaccine
  • Rising entry of new market players in the production of vaccine
• Market Challenges
  • Reduced awareness in emerging economies

Porter's Five Forces: A Strategic Tool for Navigating the Human Rabies Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Rabies Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Rabies Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Rabies Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Rabies Vaccines Market

A detailed market share analysis in the Human Rabies Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Rabies Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Rabies Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Rabies Vaccines Market

A strategic analysis of the Human Rabies Vaccines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Rabies Vaccines Market, highlighting leading vendors and their innovative profiles. These include Bavarian Nordic A/S, Bharat Biotech International Limited, Cadila Pharmaceuticals Ltd., CSC Pharmaceutical International, Indian Immunologicals Limited, Merck & Co Inc., Novartis International AG, Pfizer Inc., Sanofi SA, Serum Institute of India, Virbac, and Wyeth, LLC.

Market Segmentation & Coverage

This research report categorizes the Human Rabies Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Cell Line Type, market is studied across BHK Cells, Chick Embryo Cells, and Vero Cell.
• Based on Route of Administration, market is studied across Intravenous and Subcutaneous.
• Based on Application, market is studied across Post Exposure Prophylaxis and Pre Exposure Prophylaxis.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of mortality due to rabies
    • 5.1.1.2. Increasing number of pets and stray dogs
    • 5.1.1.3. Lower rate of immunization in pets and lack of pet management services
  • 5.1.2. Restraints
    • 5.1.2.1. Dearth of vaccine supply in remote areas
  • 5.1.3. Opportunities
    • 5.1.3.1. Proliferation in research and development activities to introduce effective vaccine
    • 5.1.3.2. Rising entry of new market players in the production of vaccine
  • 5.1.4. Challenges
    • 5.1.4.1. Reduced awareness in emerging economies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Rabies Vaccines Market, by Cell Line Type

• 6.1. Introduction
• 6.2. BHK Cells
• 6.3. Chick Embryo Cells
• 6.4. Vero Cell

7. Human Rabies Vaccines Market, by Route of Administration

• 7.1. Introduction
• 7.2. Intravenous
• 7.3. Subcutaneous

8. Human Rabies Vaccines Market, by Application

• 8.1. Introduction
• 8.2. Post Exposure Prophylaxis
• 8.3. Pre Exposure Prophylaxis

9. Human Rabies Vaccines Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Hospital Pharmacy
• 9.3. Online Pharmacy
• 9.4. Retail Pharmacy

10. Americas Human Rabies Vaccines Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Human Rabies Vaccines Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Human Rabies Vaccines Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bavarian Nordic A/S
• 2. Bharat Biotech International Limited
• 3. Cadila Pharmaceuticals Ltd.
• 4. CSC Pharmaceutical International
• 5. Indian Immunologicals Limited
• 6. Merck & Co Inc.
• 7. Novartis International AG
• 8. Pfizer Inc.
• 9. Sanofi SA
• 10. Serum Institute of India
• 11. Virbac
• 12. Wyeth, LLC